Jump to navigation Jump to search
Clinical data
Routes of
ATC code
Pharmacokinetic data
MetabolismHepatic (mainly CYP3A4)[1]
Elimination half-life1.5 hours[1]
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass481.503 g/mol

WikiDoc Resources for Pranlukast


Most recent articles on Pranlukast

Most cited articles on Pranlukast

Review articles on Pranlukast

Articles on Pranlukast in N Eng J Med, Lancet, BMJ


Powerpoint slides on Pranlukast

Images of Pranlukast

Photos of Pranlukast

Podcasts & MP3s on Pranlukast

Videos on Pranlukast

Evidence Based Medicine

Cochrane Collaboration on Pranlukast

Bandolier on Pranlukast

TRIP on Pranlukast

Clinical Trials

Ongoing Trials on Pranlukast at Clinical

Trial results on Pranlukast

Clinical Trials on Pranlukast at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Pranlukast

NICE Guidance on Pranlukast


FDA on Pranlukast

CDC on Pranlukast


Books on Pranlukast


Pranlukast in the news

Be alerted to news on Pranlukast

News trends on Pranlukast


Blogs on Pranlukast


Definitions of Pranlukast

Patient Resources / Community

Patient resources on Pranlukast

Discussion groups on Pranlukast

Patient Handouts on Pranlukast

Directions to Hospitals Treating Pranlukast

Risk calculators and risk factors for Pranlukast

Healthcare Provider Resources

Symptoms of Pranlukast

Causes & Risk Factors for Pranlukast

Diagnostic studies for Pranlukast

Treatment of Pranlukast

Continuing Medical Education (CME)

CME Programs on Pranlukast


Pranlukast en Espanol

Pranlukast en Francais


Pranlukast in the Marketplace

Patents on Pranlukast

Experimental / Informatics

List of terms related to Pranlukast

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Pranlukast is a cysteinyl leukotriene receptor-1 antagonist. This drug works similarly to Merck & Co.'s Singulair (montelukast).

Medications of this class, which go under a variety of names according to whether one looks at the American, British or European system of nomenclature, have as their primary function the antagonism of bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.

Medications of this group are normally used as an adjunct to the standard therapy of inhaled steroids with inhaled long- and/or short-acting beta-agonists. There are several similar medications in the group; all appear to be equally effective.


  1. 1.0 1.1 Nakade S, Ueda S, Ohno T, Nakayama K, Miyata Y, Yukawa E, Higuchi S (2006). "Population pharmacokinetics of pranlukast hydrate dry syrup in children with allergic rhinitis and bronchial asthma". Drug Metab Pharmacokinet. 21 (2): 133–9. PMID 16702733.

Template:Asthma and copd rx